MTR-601: A Promising Step Forward in the Treatment of Cervical Dystonia
Our lead therapeutic candidate, MTR-601, represents a potential first-in-class antispastic therapy with a unique mechanism of action that directly targets the contractile protein – myosin 2 – in fast-twitch skeletal muscle. As an oral, selective inhibitor, MTR-601 is designed to offer a non-invasive approach for the treatment of cervical dystonia, targeting fast-twitch muscle fibers with the potential to decrease stiffness and potentially improve physical function.
Body of Mechanistic Evidence
We are advancing MTR-601 on a robust body of preclinical data that demonstrates initial activity in selectively relaxing fast-twitch skeletal muscle subtypes. In a preclinical model, MTR-601 was also shown to improve gait function in spastic cerebral palsy.
Phase 2 Study Initiating in Q1 2025
Our team has completed a range of Investigational New Drug (IND)-enabling studies to generate the safety data that will enabled us to complete the first human trials of MTR-601. Our team is preparing to initiate a Phase 2 clinical trial in the first quarter of 2025.
